More

    Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with  Acquired Hypothalamic Obesity



    [
    Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with  Acquired Hypothalamic Obesity
    [og_img]
    https://www.investing.com/news/press-releases/rhythm-pharmaceuticals-to-announce-topline-results-from-pivotal-phase-3-transcend-trial-evaluating-setmelanotide-in-patients-with-acquired-hypothalamic-obesity-93CH-3969537


    Investing.com

    Latest articles

    spot_imgspot_img

    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here

    spot_imgspot_img